Doggrell Sheila A
RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia.
Expert Opin Pharmacother. 2008 Apr;9(5):869-73. doi: 10.1517/14656566.9.5.869.
Topiramate was originally developed as an anti-epileptic but has recently been tested in motivated subjects with alcohol dependency and with binge-eating disorder (BED).
Evaluation of recent clinical trials.
In the trial with subjects with alcohol dependency, the primary efficacy outcome was the percentage of heavy drinking days, which fell to a greater extent with topiramate (from 82 to 40%). In the trial with subjects with BED, the primary efficacy measure was weight change. Weight decreased from 98.4 to 97.5 kg in the placebo group, and from 96.6 to 89.8 kg in the topiramate group over 21 weeks.
Topiramate may be indicated in alcohol dependency and BED. However, it is not known whether benefits with topiramate are retained in the long term, nor whether topiramate will be effective in subjects with less resolve.
托吡酯最初是作为一种抗癫痫药物开发的，但最近已在有酒精依赖和暴饮暴食症（BED）的有动机的受试者中进行了测试。
对近期临床试验进行评估。
在针对酒精依赖受试者的试验中，主要疗效指标是重度饮酒天数的百分比，托吡酯组该指标下降幅度更大（从82%降至40%）。在针对BED受试者的试验中，主要疗效指标是体重变化。在21周内，安慰剂组体重从98.4千克降至97.5千克，托吡酯组体重从96.6千克降至89.8千克。
托吡酯可能适用于酒精依赖和BED。然而，尚不清楚托吡酯的益处是否能长期保持，也不清楚托吡酯对决心较小的受试者是否有效。
